Endogenous nitric oxide: physiology, pathology and clinical relevance

European Journal of Clinical Investigation

Volumn 21, Issue 4, 1991, Pages 361-374

  MONCADA, S ^a   HIGGS, E A ^a  

^a WELLCOME RESEARCH LABORATORIES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GUANYLATE CYCLASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

CYTOTOXICITY; HUMAN; IMMUNE RESPONSE; MACROPHAGE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE;

AMINO ACID OXIDOREDUCTASES; ANIMAL; BLOOD PLATELETS; BLOOD VESSELS; IMMUNE SYSTEM; MACROPHAGES; NERVOUS SYSTEM; NEUTROPHILS; NITRIC OXIDE; NITRIC-OXIDE SYNTHASE;

EID: 0025784834     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.1991.tb01383.x     Document Type: Review

References (190)

1. The role of endothelium in the responses of vascular smooth muscle to drugs
2. Endothelium‐dependent inhibition of platelet aggregation
3. Comparative pharmacology of endothelium‐derived relaxing factor, nitric oxide and prostacyclin in platelets
4. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium
5. Endothelium‐derived relaxing factor: identification as nitric oxide and role in the control of vascular tone and platelet function
6. Nitric oxide release accounts for the biological activity of endothelium‐derived relaxing factor
7. Quantitative and kinetic characterization of nitric oxide and EDRF released from cultured endothelial cells
8. Endothelium‐derived relaxing factor produced and released from artery and vein is nitric oxide
9. Additional evidence that endothelium‐derived relaxing factor is nitric oxide
10. Acetylcholine induces vasodilatation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodi‐lator
11. Nitric oxide release from the isolated guinea pig heart
12. The release of nitric oxide from the rabbit aorta
13. Vascular endothelial cells synthesize nitric oxide from L‐arginine
14. Arginine is a physiological precursor of endothelium‐derived nitric oxide
15. L‐arginine is the physiological precursor for the formation of nitric oxide in endothelium‐dependent relaxation
16. A novel citrulline‐forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells
17. The L‐arginine:nitric oxide pathway in the vessel wall
18. 2+ dependency converts L‐arginine into an activator of soluble guanylyl cyclase
19. Nitric oxide synthesis in endothelial cytosol: evidence for a calcium‐dependent and a calcium‐independent mechanism
20. A specific inhibitor of nitric oxide formation from L‐arginine attenuates endothelium‐dependent relaxation
21. Identification of arginine as a precursor of endothelium‐derived relaxing factor (EDRF)
22. Nitric oxide synthesized from L‐arginine regulates vascular tone in the coronary circulation of the rabbit
23. Role of endothelium‐derived nitric oxide in the regulation of blood pressure
24. G‐Methylarginine, an inhibitor of endothelium‐derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo?
25. Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation
26. G‐monomethyl‐L‐arginine in conscious rats
27. Role of endothelium‐derived relaxing factor in regulation of renal hemodynamic responses
28. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo.
29. Control of regional blood flow by endothelium‐derived nitric oxide
30. G‐monomethyl‐L‐arginine (L‐NMMA) in conscious rats
31. Effects of inhibition of nitric oxide formation on basal tone and endothelium‐dependent responses of the coronary arteries in awake dogs
32. Effects of endothelium‐derived nitric oxide on peripheral arteriolar tone in man
33. Nitric oxide synthesised from L‐arginine mediates endothelium‐dependent dilatation in human veins
34. Identification of some novel inhibitors of the vascular nitric oxide synthase in vivo and in vitro.
35. G‐Nitroarginine (NOARG) inhibits endothelium‐dependent vasodilatation in the rabbit aorta and perfused rat mesentery
36. Gnitro‐L‐arginine: a potent inhibitor of endothelium‐derived relaxing factor formation
37. 5‐[imino(nitroami‐no)methyl]‐L‐ornithine) impairs endothelium‐dependent dilations by inhibiting cytosolic nitric oxide synthesis from L‐arginine
38. G‐amino‐L‐arginine: a new potent antagonist of L‐arginine‐mediated endothelium‐dependent relaxation
39. G‐nitro‐L‐arginine methyl ester in conscious Brattleboro rats
40. Pulsatile perfusion stimulates the release of endothelial autacoids
41. Flow‐induced release of endothelium‐derived relaxing factor
42. The discovery of nitric oxide as the endogenous nitrovasodilator
43. Development and mechanism of a specific supersensitivity to nitrovasodilators following inhibition of vascular nitric oxide synthesis in vivo.
44. Venous and arterial endothelia: different dilator abilities in dog vessels
45. The effects of nitroglycerin on those who manufacture it
46. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S‐nitrosothiols as active intermediates
47. Mechanism of nitrate‐induced vasodilatation and tolerance
48. Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover
49. Desensitization to nitroglycerin in vascular smooth muscle from rat and human
50. Postjunctional supersensitivity and subsensitivity of excitable tissues to drugs
51. Effects of chronic treatment with a source of exogenous nitric oxide on the release of endothelium‐derived relaxing factor by aortae from normal and hypercholesterolaemic rabbits
52. Decreased endothelium‐dependent relaxation in New Zealand genetic hypertensive rats
53. Endothelium‐dependent reactivity in resistance vessels
54. Effect of hypertension and its reversal on endothelium‐dependent relaxations in the rat aorta
55. Vascular relaxation and cGMP in hypertension
56. Blood pressure and impairment of endothelium‐dependent relaxation in spontaneously hypertensive rats
57. Coronary artery reactivity in deoxycorticosterone acetate hypertensive rats
58. Role of endothelium in dilator responses of spontaneously hypertensive rat arteries
59. Indirect evidence for release of endothelium‐derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension
60. Abnormal endothelium‐dependent vascular relaxation in patients with essential hypertension
61. Impairment of endothelium‐dependent relaxation in aortae from spontaneously diabetic rats
62. Endothelium‐dependent relaxation to acetylcholine in the aorta of streptozotocin induced diabetic‐rat and the BB‐diabetic rat
63. Impairment of endothelium‐dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin‐induced diabetic rats
64. Advanced glycosylation products quench nitric oxide and mediate defective endothelium‐dependent vasodilatation in experimental diabetes
65. Endothelium‐dependent relaxations in isolated arteries of control and hypercholesterolemic rabbits
66. Effect of hypercholesterolemia on vascular reactivity in the rabbit. I. Endothelium‐dependent and endothelium‐independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits
67. Endothelium‐dependent relaxation and experimental atherosclerosis in the rabbit aorta
68. Impaired endothelium‐dependent relaxation and cyclic guanosine 5′‐monophos‐phate formation in atherosclerotic human coronary artery and rabbit aorta
69. Mechanisms of abnormal endothelium‐dependent vascular relaxation in atherosclerosis: implications for altered autocrine and paracrine functions of EDRF
70. Properties and mechanisms of production and action of endothelium‐derived relaxing factor
71. Coronary artery spasm induced in atherosclerotic miniature swine
72. Flow‐dependent coronary artery dilatation in humans
73. Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries
74. Inhibition of endothelium‐derived nitric oxide and atherosclerosis
75. Reduced endothelium‐dependent relaxation of cystic fibrosis pulmonary arteries
76. Impairment of pulmonary endothelium‐dependent relaxation in patients with Eisenmenger's syndrome
77. Physiological and histological correlates of pulmonary endothelium‐dependent relaxation in human chronic obstructive lung disease
78. The correlation of cerebral vasospasm and the amount of subarachnoid blood detected by computerized cranial tomography after aneurysm rupture
79. Endothelium‐dependent relaxation of canine basilar arteries. II. Inhibition by hemoglobin and cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhage
80. An L‐arginine:nitric oxide pathway present in human platelets regulates aggregation
81. Adenine nucleotides, serotonin, and endothelium‐dependent relaxations to platelets
82. The anti‐aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide
83. 1 and isosorbide dinitrate in peripheral vascular disease
84. Activation of cerebral guanylate cyclase by nitric oxide
85. Endogenous activating factor for guanylate cyclase in synaptosomal‐soluble fraction of rat brain
86. Characterization of cerebellar guanylate cyclase using N‐methyl‐N‐nitro‐N‐nitrosoguani‐dine. Presence of two different types of guanylate cyclase in soluble and particulate fraction
87. L‐arginine identified as an endogenous activator for soluble guanylate cyclase from neuroblastoma cells
88. Formation of nitric oxide from L‐arginine in the central nervous system. A transduction mechanism for stimulation of the soluble guanylate cyclase
89. Endothelium‐derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain
90. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices
91. Nitric oxide mediates glutamate‐linked enhancement of cGMP levels in the cerebellum
92. Inhibition of nitric oxide synthase blocks N‐methyl‐D‐aspartate‐, quisqualate‐, kainate‐, harmaline‐ and pentylenetetra‐zole‐dependent increases in cerebellar cyclic GMP in vivo.
93. A kainate receptor linked to nitric oxide synthesis from arginine
94. Calcium ion effects on guanylate cyclase of brain
95. Kinetic characteristics of nitric oxide synthase from rat brain
96. Enzymatic formation of nitrogen oxides from L‐arginine in bovine brain cytosol
97. Isolation of nitric oxide synthetase, a calmodulin‐requiring enzyme
98. Endogenous nitric oxide release required for long‐term synaptic depression in the cerebellum
99. Cyclic GMP
100. Excitotoxicity and the NMDA receptor
101. Glutamate neurotoxicity and diseases of the nervous system
102. NMDA receptors, neuronal development and neuronal degeneration
103. Messenger molecules in the cerebellum
104. Cyclic GMP accumulation causes degeneration of photoreceptor cells: simulation of an inherited disease
105. Elevation of cyclic GMP levels in central nervous system by excitatory and inhibitory amino acids
106. Seizures and related epileptiform activity in hippocampus transplanted to the anterior chamber in the eye. II. Modulation by cholinergic and adrenergic input
107. Protection against ischaemic neuronal damage by drugs acting on excitatory neurotransmission
108. The neurotransmitter of the non‐adrenergic non‐cholinergic inhibitory nerves to smooth muscle of the genital system
109. Modulation of autonomic neuroeffector transmission by nitric oxide‐like activity in guinea‐pig smooth muscle
110. Nitric oxide from L‐arginine stimulates the soluble guanylate cyclase in adrenal glands
111. Possible muscarinic regulation of catecholamine secretion mediated by cyclic GMP in isolated bovine adrenal chromaffin cells
112. Effect of sodium azide on catecholamine release from isolated adrenal gland and on guanylate cyclase
113. Cyclic GMP regulates nicotine‐induced secretion from cultured bovine adrenal chromaffin cells. Effects of 8‐bromo‐cyclic GMP, atrial natriuretic peptide, and nitroprusside (nitric oxide)
114. Regulatory role of guanosine 3′,5′‐monophosphate in adrenocorticotropin hormone‐induced steroidogenesis
115. Endothelium‐derived relaxing factor (EDRF): the endogenous activator of soluble guanylate cyclase in various types of cells
116. Production of an EDRF‐like activity in the cytosol of N1E‐115 neuroblastoma cells
117. 1 kidney epithelial cells is L‐arginine‐dependent
118. Synthesis of a nitric oxide‐like factor from L‐arginine by rat serosal mast cells: stimulation of guanylate cyclase and inhibition of platelet aggregation
119. Blood nitrates and infantile methemoglobinemia
120. 3 into nitrate is enhanced by endotoxin treatment
121. N‐nitroso compounds: occurrence, biological effects and relevance to human cancer
122. Macrophage synthesis of nitrite, nitrate and N‐nitrosamines: precursors and role of the respiratory burst
123. L‐arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells
124. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages
125. Macrophage oxidation of L‐arginine to nitrite and nitrate: nitric oxide is an intermediate
126. Nitric oxide: a cytotoxic activated macrophage effector molecule
127. Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium‐derived relaxing factor and the chemical reactivity of nitric oxide
128. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells
129. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide
130. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines or interferon‐γy
131. Synthesis of nitrite and nitrate in murine macrophage cell lines
132. Identification of N‐iminoethyl‐L‐ornithine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells
133. Macrophage oxidation of L‐arginine to nitric oxide, nitrite and nitrate. Tetrahydrobiopterin is required as a cofactor
134. Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages
135. FAD and GSH participate in macrophage synthesis of nitric oxide
136. Synthesis of nitric oxide from a terminal guanidino nitrogen atom of L‐arginine: a molecular mechanism regulating cellular proliferation that targets intracellular iron
137. Macrophage‐mediated fungistasis in vitro: requirements for intracellular cytotoxicity
138. Macrophage‐mediated fungistasis: requirements for a macromolecular component in serum
139. Micro‐biostatic effect of murine macrophages for Toxoplasma gondii: role of synthesis of inorganic nitrogen oxides from L‐arginine
140. Activated macrophages destroy intracellular Leishmania major amasti‐gotes by an L‐arginine dependent killing mechanism
141. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L‐arginine
142. Tumor necrosis factor and granulocyte macrophage‐colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates
143. Interaction of neutrophils with vascular smooth muscle: identification of a neutrophil‐derived relaxing factor
144. Rat polymorphonuclear leukocytes (PMN) increase cGMP levels in rat aorta
145. Human monocytes and neutrophils inhibit platelet aggregation by releasing an EDRF‐like factor
146. Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide‐like factor
147. Synthesis of nitric oxide from L‐arginine by neutrophils. Release and interaction with superoxide anion
148. 4
149. Generation of nitric oxide by human neutrophils
150. An L‐arginine dependent mechanism mediates Kupffer cell inhibition of hepatocyte protein synthesis in vitro.
151. Hepatocytes produce nitrogen oxides from L‐arginine in response to inflammatory products from Kupffer cells
152. Differential induction of brain, lung and liver nitric oxide synthase by endotoxin in the rat
153. The L‐arginine dependent effector mechanism is induced in murine adenocarcinoma cells by culture supernatant from cytotoxic activated macrophages
154. Antiproliferative activity of γy‐interferon combined with lipopolysaccharide on murine adenocarcinoma: dependence on an L‐arginine metabolism with production of nitrite and citrulline
155. Antitumour cytostatic effect of EMT6 cells treated with interferon‐γy and lipopolysaccharide
156. Tetrahydrobiopterin‐dependent formation of nitrite and nitrate in murine fibroblasts
157. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells
158. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone. An insight into endotoxin shock
159. Antiinflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat
160. Myocardial and circulatory effects of E. Coli endotoxin; modification of responses to catecholamines
161. Diminution of contractile response of the aorta from endotoxin‐injected rats
162. Prolonged exposure of rat aorta to low levels of endotoxin in vitro results in impaired contractility: association with vascular cytokine release
163. Incubation with endotoxin activates the L‐arginine pathway in vascular tissue
164. Inducible cytosolic enzyme activity for the production of nitrogen oxides from L‐arginine in hepatocytes
165. G‐monomethyl‐L‐arginine in vivo promotes hepatic damage in response to lipopolysaccharide
166. Role of nitric oxide in maintaining vascular integrity in endotoxin‐induced acute intestinal damage in the rat
167. G‐methyl‐L‐arginine inhibits tumor necrosis factor‐induced hypotension: implications for the involvement of nitric oxide
168. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopoly‐saccharides in the rat in vivo
169. Circulatory changes in chronic liver disease
170. Hemodynamic and hormonal alterations in hepatic cirrhosis
171. Hepatic and systemic hemodynamics and the neurohumoral systems in cirrhosis
172. Effects of endogenous nitric oxide inhibition on the hemodynamic changes of portal hypertensive rats
173. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral blood in patients with cirrhosis
174. A simple turbidometric time assay of the endotoxin in plasma
175. Atrial natriuretic peptide in liver cirrhosis with mild ascites
176. Hypothesis: induction of nitric oxide synthase in the vasculature underlies the hyperdynamic circulation of cirrhosis
177. 100 septic shock following steroid/antibiotic therapy
178. Experimental gram‐negative bacterial sepsis: optimal methyl‐prednisolone requirements for prevention of mortality not preventable by antibiotics alone
179. Glucocorticoids in the treatment of shock and the adult respiratory distress syndrome
180. Reduction of mortality in chloramphenicol‐treated severe typhoid fever by high‐dose dexamethasone
181. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogues: inhibitors of adrenocortical steroid biosynthesis
182. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages
183. Glucocorticoid‐induced impairment of macrophage antimicrobial activity: mechanisms and dependence on the state of activation
184. Effects of various inhibitors of arachidonic acid oxygenation on macrophage superoxide release and tumoricidal activity
185. Inhibition of macrophage tumoricidal activity by glucocorticoids
186. Update on systemic necrotizing vasculitis
187. Biosynthesis of nitric oxide from L‐arginine: a pathway for the regulation of cell function and communication
188. Uber di Zuchtung der Erysipelkokken auf kunst‐lichen Nahrboden und ihr Ubertragbarkeit auf den Menschen. Dt. med.
189. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases